Related Experiment Video
Updated: Sep 26, 2025
Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia
Yufeng Xi1, Rong Ju1, Yujia Wang1,2
1Department of Neonatology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Insights
Mesenchymal stromal cells derived extracellular vesicles (MSC-EVs) show promise for treating bronchopulmonary dysplasia (BPD) in premature infants. These cell-free therapies promote lung repair by delivering therapeutic biomolecules, though clinical application faces challenges.
Area of Science:
- Regenerative Medicine
- Nanomedicine
- Neonatal Respiratory Health
Background:
- Bronchopulmonary dysplasia (BPD) is a prevalent chronic respiratory disease in premature infants with limited treatment options.
- Mesenchymal stromal cells derived extracellular vesicles (MSC-EVs) are key mediators of intercellular communication, facilitating tissue repair.
- MSC-EVs, containing proteins and nucleic acids, are recognized for their therapeutic potential in organ injury via biomolecule delivery.
Purpose of the Study:
- To explore the therapeutic potential of MSC-EVs in treating lung injury associated with BPD.
- To elucidate the mechanisms by which MSC-EVs promote pulmonary vascular and alveolar development.
- To assess the regenerative capabilities of MSC-EVs in addressing inflammation and oxidative stress in BPD.
Main Methods:
- Investigated the role of MSC-EVs in promoting pulmonary vessel and alveolar development.
- Analyzed the impact of MSC-EVs on reducing pulmonary hypertension and inflammation in lung injury models.
- Examined the regenerative mechanisms of MSC-EVs, including regulation of cell proliferation, survival, migration, differentiation, and angiogenesis.
Main Results:
- MSC-EVs demonstrated significant promotion of pulmonary vessel and alveolar development.
- Treatment with MSC-EVs led to reduced pulmonary hypertension and inflammation.
- MSC-EVs effectively regulated key cellular processes like proliferation, survival, migration, differentiation, angiogenesis, and oxidative stress.
Conclusions:
- MSC-EVs represent a promising cell-free therapeutic strategy for lung injury and BPD due to their regenerative and anti-inflammatory properties.
- Their non-immunogenic nature, ability to penetrate tissues, and potential for drug modification enhance their therapeutic prospects.
- Further research and development are necessary to overcome challenges and facilitate the clinical application of MSC-EVs for BPD treatment.
Abstract:
Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease in premature infants. However, there is a lack of effective treatment. Mesenchymal stromal cells derived extracellular vesicles (MSC-EVs), as nano- and micron-sized heterogeneous vesicles secreted by MSCs, are the main medium for information exchange between MSCs and injured tissue and organ, playing an important role in repairing tissue and organ injury. EVs include exosomes, microvesicles and so on. They are rich with various proteins, nucleic acids, and lipids. Now, EVs are considered as a new way of cell-to-cell communication. EVs mainly induce regeneration and therapeutic effects in different tissues and organs through the biomolecules they carry. The surface membrane protein or loaded protein and nucleic acid molecules carried by EVs, can activate the signal transduction of target cells and regulate the biological behavior of target cells after binding and cell internalization. MSC-EVs can promote the development of pulmonary vessels and alveoli and reduce pulmonary hypertension (PH) and inflammation and play an important role in the repair of lung injury in BPD. The regeneration potential of MSC-EVs is mainly due to the regulation of cell proliferation, survival, migration, differentiation, angiogenesis, immunoregulation, anti-inflammatory, mitochondrial activity and oxidative stress. As a new type of cell-free therapy, MSC-EVs have non-immunogenic, and are small in size and go deep into most tissues. What's more, it has good biological stability and can be modified and loaded with drugs of interest. Obviously, MSC-EVs have a good application prospect in the treatment of lung injury and BPD. However, there are still many challenges to make MSC-EVs really enter clinical application.
